Status:
COMPLETED
Relative Bioavailability of 2 Fixed Dose Combinations of Linagliptin/Metformin Compared With Single Tablets
Lead Sponsor:
Boehringer Ingelheim
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
The purpose of the trial is to demonstrate the relative bioavailability of 2 newly developed fixed dose combination (FDC) tablets containing linagliptin \& metformin and the single tablets of linaglip...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Healthy males or females
- Age 18 -50 years (incl)
- Body Mass Index (BMI) 18.5 to 29.9 kg/m2 (incl.)
- Subjects must be able to understand and comply with study requirements
- Exclusion criteria:
- Any deviation from healthy condition
Exclusion
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT01845077
Start Date
May 1 2013
End Date
August 1 2013
Last Update
August 19 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1288.8.1 Boehringer Ingelheim Investigational Site
Austin, Texas, United States